Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutically active pyrrolidine ester derivatives

a technology of pyrrolidine and ester, which is applied in the field of pyrrolidine esters, can solve the problems of significant problems in the management of preterm labor, undesired prematurity birth, and perinatal morbidity and mortality

Inactive Publication Date: 2007-06-07
MERCK SERONO SA
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention is about using certain chemicals called pyrrolidine esters to treat and prevent premature labor, premature birth, and dysmenorrhea. These chemicals work by blocking a specific receptor called the oxytocin receptor. The invention also includes new types of pyrrolidine esters."

Problems solved by technology

Premature labor, though, and premature birth is undesired as it represents a major cause of perinatal morbidity and mortality.
Hence, the management of preterm labor represents a significant problem in the field of obstetrics.
Magnesium sulfate at plasma concentrations above the therapeutic range of 4 to 8 mg / dL can cause inhibition of cardiac conduction and neuromuscular transmission, respiratory depression and cardiac arrest, thus making this agent unsuitable when renal function is impaired.
Ethanol is as effective as ritodrine in preventing premature labor, but it does not produce a corresponding reduction in the incidence of fetal respirator distress that administration of ritodrine does.
The principal drawback to the use of peptide antagonists including also atosiban is the problem of low oral bioavailability resulting from intestinal degradation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutically active pyrrolidine ester derivatives
  • Pharmaceutically active pyrrolidine ester derivatives
  • Pharmaceutically active pyrrolidine ester derivatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Procedure for the Saponification of Methylesters of Oximether and / or Olefin-type 2-pyrrolidinecarboxylic Acid Intermediates (Schemes 3, 7)

[0136] A solution of sodium hydroxide (73 mg, 1.81 mmol) in water (1.2 ml) was added to a proline oximether methyl ester derivative, e.g. methyl (2S,4EZ)-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxylate (391 mg, 1.1 mmol) in 3:1 dioxane:water (12 ml) and the reaction stirred for 3 h. The reaction mixture was then washed with diethyl ether (2×10 ml), and the aqueous phase acidified to pH 2 (0.1N HCl) and extracted into ethyl acetate. The ethyl acetate layer was then dried over magnesium sulfate, filtered and the solvent was then removed in vacuo to give the desired product, e.g. (2S4EZ)-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidine-carboxylic acid in 91% yield as an oil which was used without further purification.

[0137]1H NMR (300 MHz, CDCl3): 2.25 (m, 3H, ArCH3), 2.96-3.3...

example 2

General Protocols for the Esterification of Oximeter- and / or Olefin-type 2-pyrrolidinecarboxylic Acid Intermediates (Schemes 2, 5, 7):

a) Methylesters (e.g. 1-tert-butyl 2-methyl (2S,4EZ)-4-(methoxyimino)-1,2-pyrrolidine-dicarboxylate):

[0138] A solution of the oximether- and / or olefin-type 2-pyrrolidinecarboxylic acid intermediate, e.g. (2S,4EZ)-1-(tert-butoxycarbonyl)-4-(methoxyimino)-2-pyrrolidinecarboxylic acid (0.648 g, 2.5 mmol), in a 1:1 mixture of methanol and toluene (35 ml) was made. Trimethylsilyl diazomethane (3.8 ml of a 2M solution in hexanes, 7.5 mmol) was then added dropwise to the stirred solution at room temperature under nitrogen. After completion of the evolution of nitrogen gas, the resulting yellow solution was evaporated in vacuo, and the residue filtered through a pad of silica gel, eluting with ethyl acetate. Removal of solvent from the filtrate gave the methylester product, e.g. 1-tert-butyl 2-methyl (2S,4EZ)-4-(methoxyimino)-1,2-pyrrolidinedicarboxylate,...

example 3

Cyclopentyl (2S,4EZ)-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxylate

[0141] Following the general methods as outlined in Example 2, starting from (2S,4EZ)-4-(methoxyimino)-1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxylic acid and cyclopentanol, the title compound was isolated, after flash-chromatography, as a mixture of two isomers as an oil in 57% yield (95.6% purity by HPLC).

[0142]1H NMR (300 MHz, CDCl3): 1.47-1.98 (m, 8H), 2.24 (m, 3H, ArCH3), 2.73-3.14 (m, 2H), 3.84 (m, 3H, NOCH3), 4.11-4.46 (m, 2H), 4.61 (br s, 1H), 4.99-5.32 (m, 2H), 7.15-7.28 (m, 4H), 7.31-7.41 (m, 2H), 7.51-7.62 (m, 2H). M+(APCI+): 421.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
volumeaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR6R7, NOR6, NNR6R7; R is selected from the group comprising or consisting of C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl. R1 is selected from the group comprising or consisting of C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, 3-8-membered cycloalkyl, acyl, C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1-2 further cycloalkyl or aryl or heteroaryl group.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application is a division of U.S. Ser. No. 10 / 471,290, filed on Sep. 22, 2003 (371 completion date Feb. 23, 2004), which is a National Stage (371) of PCT / EP02 / 03005, filed on Mar. 19, 2002, which claims priority to EP 01106888.9, filed on Mar. 20, 2001.FIELD OF THE INVENTION [0002] The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonise the oxytocin receptor. The present invention is furthermore also related to novel pyrrolidine esters. BACKGROUND OF THE INVENTION [0003] Oxytocin (OT) is a peptide hormone and causes the contraction of the uterus of mammals during labor. The corresponding oxytocin receptor belongs to the family of G-protein-coupled receptors and is similar to V1a and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/506A61K31/4439A61K31/401C07D403/02A61K31/40A61P15/00A61P15/06A61P43/00C07D207/20C07D207/22C07D401/10C07D403/10
CPCA61K31/401C07D207/22C07D401/10C07D403/10A61P15/00A61P15/06A61P43/00
Inventor SCHWARZ, MATTHIASQUATTROPANI, ANNASCHEER, ALEXANDERDORBAIS, JEROMEPOMEL, VINCENT
Owner MERCK SERONO SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com